Study of NGEP expression pattern in cancerous tissues provides novel insights into prognostic marker in prostate cancer

Biomarkers in Medicine

Volumn 9, Issue 4, 2015, Pages 391-401

  Mohsenzadegan, Monireh ^a,b   Shekarabi, Mehdi ^a   Madjd, Zahra ^a   Asgari, Mojgan ^a,c   Abolhasani, Maryam ^a,c   Tajik, Nader ^a,b   Farajollahi, Mohammad M ^b,d  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d Alborz Food and Drug Laboratory   (Iran)

Author keywords

anti peptide antibody; NGEP; prognostic factors; prostate cancer

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; AMINO ACID CYTOPLASMIC PROTEIN; AMINO ACID MEMBRANE PROTEIN; ANTIBODIES,ANTISERA AND IMMUNOGLOBULINS; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; NGEP P1 ANTIBODY; NGEP P2 ANTIBODY; NGEP PROTEIN; POLYCLONAL ANTIBODY; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROSTATE STEM CELL ANTIGEN; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; AMINO ACID SEQUENCE; ANIMAL CELL; ANTIBODY PRODUCTION; ANTIBODY TITER; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; BIOTINYLATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GLEASON SCORE; GLYCOSYLATION; HUMAN; HUMAN TISSUE; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NONHUMAN; PROGNOSIS; PROSTATE CANCER; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN TARGETING; RABBIT; TISSUE SPECIFICITY; TUMOR DIFFERENTIATION; VERY ELDERLY; WESTERN BLOTTING;

EID: 84964252116     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.14.106     Document Type: Article

References (27)

1. Kopper L, Timar J. Genomics of prostate cancer: is there anything to "translate"? Pathol. Oncol. Res. 11(4), 197-203 (2005).
2. Vainio P, Lehtinen L, Mirtti T et al. Phospholipase PLA2G7, associated with aggressive prostate cancer, promotes prostate cancer cell migration and invasion and is inhibited by statins. Oncotarget 2(12), 1176-1190 (2011).
3. Ferlay J, Autier P, Boniol M et al. Estimates of the cancer incidence and mortality in Europe. Ann. Oncol. 18(3), 581-592 (2007).
4. Netto GJ. Molecular diagnostics in urologic malignancies: a work in progress. Arch. Pathol. Lab. Med. 135(5), 610-621 (2011).
5. Netto GJ, Epstein JI. Theranostic and prognostic biomarkers: genomic applications in urological malignancies. Pathology 42(4), 384-394 (2010).
6. Choudhury AD, Eeles R, Freedland SJ et al. The role of genetic markers in the management of prostate cancer. Eur. Urol. 62(4), 577-587 (2012).
7. Karnes RJ, Whelan CM, Kwon ED. Immunotherapy for prostate cancer. Curr. Pharm Des. 12(7), 807-817 (2006).
8. Koh YT, Gray A, Higgins SA et al. Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization. Prostate 69(6), 571-584 (2009).
9. Harada M, Matsueda S, Yao A et al. Vaccination of cytotoxic T lymphocyte-directed peptides elicited and spread humoral and Th1-Type immune responses to prostate-specific antigen protein in a prostate cancer patient. J. Immunother. 28(4), 368-375 (2005).
10. Corcoran NM, Casey RG, Hong MK et al. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume. BJU Int. 110(1), 36-42 (2012).
11. Kalos M, Askaa J, Hylander BL et al. Protein expression is highly restricted to normal and malignant prostate tissues. Prostate 60(3), 246-256 (2004).
12. Ruan Y, Yu W, Cheng Fan et al. Detection of prostate stem cell antigen expression in human prostate cancer using quantum-dot-based technology. Sensors 12(5), 5461-5470 (2012).
13. Kinoshita Y, Kuratsukuri K, Landas S et al. Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J. Surg. 30(4), 628-636 (2006).
14. Drake CG. Prostate cancer as a model for tumour immunotherapy. Nat. Rev. Immunol. 10(8), 580-593 (2010).
15. Bera TK, Das S, Maeda H et al. NGEP, a gene encoding a membrane protein detected only in prostate cancer and normal prostate. Proc. Natl Acad. Sci. USA 101(9), 3059-3064 (2004).
16. Das S, Hahn Y, Nagata S et al. NGEP, a prostate-specific plasma membrane protein that promotes the association of LNCaP cells. Cancer Res. 67(4), 1594-1601 (2007).
17. Das S, Hahn Y, Walker DA et al. Topology of NGEP, a prostate specific cell: cell junction protein widely expressed in many cancers of different grade level. Cancer Res. 68(15), 6306-6312 (2008).
18. Cereda V, Poole DJ, Palena C et al. New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy. Cancer Immunol. Immunother. 59(1), 63-71 (2010).
19. Gulley JL, Heery CR, Madan RA et al. Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer. Cancer Immunol. Immunother. 62(9), 1521-1531 (2013).
20. Duran C, Qu Z, Osunkoya AO et al. ANOs 3-7 in the anoctamin/Tmem16 Cl-channel family are intracellular proteins. Am. J. Physiol. Cell Physiol. 302(3), C482-C493 (2012).
21. Hartzell HC, Yu K, Xiao Q et al. Anoctamin/TMEM16 family members are Ca2+-activated Cl-channels. J. Physiol. 587(Pt 10), 2127-2139 (2009).
22. Mohsenzadegan M, Madjd Z, Asgari M et al. Reduced expression of NGEP is associated with high-grade prostate cancers: a tissue microarray analysis. Cancer Immunol. Immunother. 62(10), 1609-1618 (2013).
23. Farajollahi MM, Cook DB, Hamzehlou S et al. Reduction of non-specific binding in immunoassays requiring long incubations. Scand. J. Clin. Lab. Invest. 72(7), 531-539 (2012).
24. Watson NF, Spendlove I, Madjd Z et al. Expression of the stress-related MHC class I chain-related protein MICA is an indicator of good prognosis in colorectal cancer patients. Int. J. Cancer 118(6), 1445-1452 (2006).
25. Madjd Z, Karimi A, Molanae S et al. BRCA1 protein expression level and CD44(+) phenotype in breast cancer patients. Cell J. 13(3), 155-162 (2011).
26. Fine SW, Amin MB, Berney DM et al. A contemporary update on pathology reporting for prostate cancer: biopsy and radical prostatectomy specimens. Eur. Urol. 62(1), 20-39 (2012).
27. Zarour HM, Ferrone S. Cancer immunotherapy: progress and challenges in the clinical setting. Eur. J. Immunol. 41(6), 1510-1515 (2011).